ConductScience.org, home

Paper42582425

Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist.

Ramadurgum P and 3 others. Front Pharmacol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist. Papers, record 42582425. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42582425

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist.
PubMed
Journal
Front Pharmacol
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ramadurgum PPrerana
2Shah JJoel
3Shah EEmily
4Palmer BFBiff F

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References27

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112190331Mechanisms of clinically relevant drug interactions associated with tacrolimus.Clin Pharmacokinet2002https://conductscience.org/library/papers/12190331PubMed
240129942Semaglutide promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells through activation of the Wnt/LRP5/β-catenin signaling pathway.Front Pharmacol2025https://conductscience.org/library/papers/40129942PubMed
341506360Acute kidney injury: Detection, risk stratification, and predictive biomarkers.Clin Chim Acta2026https://conductscience.org/library/papers/41506360PubMed
441683830Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes.Int J Mol Sci2026https://conductscience.org/library/papers/41683830PubMed
538742021Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity.Front Nutr2024https://conductscience.org/library/papers/38742021PubMed
639728000Spotlight on the Mechanism of Action of Semaglutide.Curr Issues Mol Biol2024https://conductscience.org/library/papers/39728000PubMed
722205779Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.Drug Metab Dispos2012https://conductscience.org/library/papers/22205779PubMed
840544435Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.N Engl J Med2025https://conductscience.org/library/papers/40544435PubMed
938796653Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.Nat Med2024https://conductscience.org/library/papers/38796653PubMed
1139364792Glucagon-like peptide-1 receptor agonists and kidney outcomes.J Diabetes2024https://conductscience.org/library/papers/39364792PubMed
1241880122GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes.Curr Cardiol Rep2026https://conductscience.org/library/papers/41880122PubMed
1338414573Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis.Obes Sci Pract2024https://conductscience.org/library/papers/38414573PubMed
1438785209Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.N Engl J Med2024https://conductscience.org/library/papers/38785209PubMed
1537344954
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
Diabetes Obes Metab2023https://conductscience.org/library/papers/37344954PubMed
1633449915Decreased expression of the GLP-1 receptor after segmental artery injury in mice.J Endocrinol2021https://conductscience.org/library/papers/33449915PubMed
1733177239Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.Proc Natl Acad Sci U S A2020https://conductscience.org/library/papers/33177239PubMed
1818388866Emerging evidence of the impact of kidney disease on drug metabolism and transport.Clin Pharmacol Ther2008https://conductscience.org/library/papers/18388866PubMed
1940920377GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes.JAMA Netw Open2025https://conductscience.org/library/papers/40920377PubMed
2028538729Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein.Nature2017https://conductscience.org/library/papers/28538729PubMed
2139856432Semaglutide administration protects cardiomyocytes in db/db mice via energetic improvement and mitochondrial quality control.Acta Pharmacol Sin2025https://conductscience.org/library/papers/39856432PubMed

See all 27 referencesDownload CSV of references

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ARRB1408PubTator's text mininghttps://conductscience.org/library/genes/408NCBI Gene
GLP1R2740PubTator's text mininghttps://conductscience.org/library/genes/2740NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42582425

GET https://conductscience.org/api/papers/v1/42582425/references?page=2